Why Milestone Pharmaceuticals Inc.’s (MIST) Stock Is Up 6.25%
As of Tuesday, August 25, Milestone Pharmaceuticals Inc.’s MIST share price has surged by 6.25%, which has investors questioning if this is right time to sell.Jenna Brashear
Stock Evaluator: Milestone Pharmaceuticals Inc. (MIST)
Milestone Pharmaceuticals Inc. MIST
$1.21
0.03
2.54%
September 3, 2026 4:00:00 PM
EST
Volume: 2,010,151
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Commentary & Analysis
Why Milestone Pharmaceuticals Inc.’s (MIST) Stock Is Down 11.97%
As of Wednesday, August 12, Milestone Pharmaceuticals Inc.’s MIST share price has dipped by 11.97%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Milestone Pharmaceuticals Inc.’s (MIST) Stock Is Down 5.22%
As of Friday, July 31, Milestone Pharmaceuticals Inc.’s MIST share price has dipped by 5.22%, which has investors questioning if this is right time to buy.Michael Rose
Why Milestone Pharmaceuticals Inc.’s (MIST) Stock Is Up 7.21%
As of Thursday, July 30, Milestone Pharmaceuticals Inc.’s MIST share price has surged by 7.21%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Milestone Pharmaceuticals Inc.’s (MIST) Stock Is Down 5.32%
As of Tuesday, July 28, Milestone Pharmaceuticals Inc.’s MIST share price has dipped by 5.32%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | MIST | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $166.3 | $674.0 | 26% |
|
| Shares Out (Mil) | 138.7 | 43.9 | 69% |
|
| Institutional Ownership | 96.7% | 84.7% | 71% |
|
| Float (Mil) | 106.5 | 47.3 | 62% |
|
| Beta | 0.98 | 0.71 | 59% |
|
| Avg Daily Volume (000s) | 1,330 | 293 | 77% |
|
| Price Change (52-week) |
(35.9%) | 68.8% | 21% |
|
| Growth | MIST | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.8% | na |
|
| Net Income (5yr) | (4.8%) | (1.5%) | 34% |
|
| EPS (5yr) | 15.1% | 14.9% | 57 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 18.7% | (15.1%) | 78% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.212) | ($0.838) | ($0.772) | |
| Month Ago EPS | ($0.210) | ($0.830) | ($0.908) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.210) | ($0.973) | ($1.045) | |
| Year/Year Chg | 2.9% | 11.4% | (63.7%) | |
| Financials | MIST | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $317 | 3% |
|
| Net Income (TTM) (Mil) | ($84) | ($11) | 12% |
|
| EPS (TTM) | ($0.712) | ($0.700) | 24% |
|
| Operating Cash Flow (TTM) (Mil) | ($61) | ($7) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $127 | $4 | 79% |
|
| Long-Term Debt (Q1) (Mil) | $141 | $6 | 47% |
|
| Enterprise Value (Q1) (Mil) | $116 | $575 | 22% |
|
| Valuation | MIST | Industry Median |
Percentile (All Stocks) |
|
| P/B | 9.08 | 2.80 | 89% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | MIST | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 98.0% | 67.5% | 96% |
|
| Net Margin | na | (1.4%) | na |
|
| ROA | (73.4%) | (24.6%) | 8% |
|
| ROE | na | (21.4%) | na |
|
| Liabilities to Assets | 90.0% | 32.2% | 86% |
|
| F-Score | 3 | 3 | 18% |
|
Milestone Pharmaceuticals Inc. did not pass any screens on 9/2/2026.
